These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29799059)

  • 1. Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities.
    Tanahashi T; Yoshida K; Yamaguchi K; Okumura N; Takeno A; Fujitani K; Fukushima N; Takiguchi N; Nishida Y; Boku N; Yoshikawa T; Terashima M
    Gastric Cancer; 2019 Jan; 22(1):130-137. PubMed ID: 29799059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
    Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
    Yamashita K; Kurokawa Y; Yamamoto K; Hirota M; Kawabata R; Mikami J; Masuzawa T; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2017 Sep; 24(9):2639-2645. PubMed ID: 28608116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of body weight loss in gastrectomy patients who underwent only surgery and those who underwent surgery followed up with S-1 adjuvant chemotherapy].
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Ogata T; Cho H; Yukawa N; Oshima T; Rino Y; Ozawa Y; Kitani Y; Wada H; Masuda M; Tsuburaya A
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):1794-6. PubMed ID: 23267889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
    Hasegawa H; Fujitani K; Kurokawa Y; Hirao M; Nakazuru S; Mita E; Tsujinaka T
    Chemotherapy; 2010; 56(6):436-43. PubMed ID: 21088394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
    Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
    Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
    Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
    Aoyama T; Kawabe T; Fujikawa H; Hayashi T; Yamada T; Tsuchida K; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
    Ann Surg Oncol; 2015 Aug; 22(8):2560-6. PubMed ID: 25515199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer.
    Aoyama T; Sato T; Maezawa Y; Kano K; Hayashi T; Yamada T; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
    Int J Clin Oncol; 2017 Jun; 22(3):476-483. PubMed ID: 28176023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical Impact of adjuvant chemotherapy in patients with T1N2/3 Gastric cancer].
    Tsuchida K; Kunisaki C; Watanabe T; Ono H; Oshima T; Fukushima T; Yoshikawa T; Rino Y; Imada T; Masuda M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2239-41. PubMed ID: 25731482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
    Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Fukushima N; Hato S; Choda Y; Yabusaki H; Yoshida K; Ito S; Takeno A; Yasuda T; Kawachi Y; Katayama H; Fukuda H; Boku N; Sano T; Sasako M
    Lancet Gastroenterol Hepatol; 2019 Mar; 4(3):208-216. PubMed ID: 30679107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of Post-Gastrectomy Adjuvant S-1 Chemotherapy on Muscle Volume in Gastric Cancer Patients].
    Iwazawa T; Kawanishi K; Fujita J; Takata A; Hirota M; Imamura H; Ikeda A; Hokonohara K; Yoneyama C; Kameyama A; Shinke G; Oshima K; Tanida T; Hatano H; Noda T; Komori T; Morita S; Akagi K; Dono K
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):957-60. PubMed ID: 26321709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
    Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
    BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
    Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
    Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
    Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
    Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients.
    Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
    Gastric Cancer; 2012 Jan; 15(1):76-82. PubMed ID: 21717091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
    Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
    Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Examination of continuity of S-1 adjuvant chemotherapy for gastric cancer patients after gastrectomy].
    Kawabata R; Imamura H; Kishimoto T; Anami S; Yasui Y; Fujino M; Fujii C; Sumida R; Furukawa H
    Gan To Kagaku Ryoho; 2011 May; 38(5):793-5. PubMed ID: 21566439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002).
    Kinoshita T; Sasako M; Sano T; Katai H; Furukawa H; Tsuburaya A; Miyashiro I; Kaji M; Ninomiya M
    Gastric Cancer; 2009; 12(1):37-42. PubMed ID: 19390930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
    Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.